HomeCompareARPO vs MO

ARPO vs MO: Dividend Comparison 2026

ARPO yields 90.91% · MO yields 6.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ARPO wins by $2.59M in total portfolio value
10 years
ARPO
ARPO
● Live price
90.91%
Share price
$2.20
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.67M
Annual income
$842,999.04
Full ARPO calculator →
MO
Altria Group Inc.
● Live price
6.36%
Share price
$65.99
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$30,159.17
Full MO calculator →

Portfolio growth — ARPO vs MO

📍 ARPO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodARPOMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ARPO + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ARPO pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ARPO
Annual income on $10K today (after 15% tax)
$7,727.27/yr
After 10yr DRIP, annual income (after tax)
$716,549.18/yr
MO
Annual income on $10K today (after 15% tax)
$540.99/yr
After 10yr DRIP, annual income (after tax)
$25,635.29/yr
At 15% tax rate, ARPO beats the other by $690,913.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ARPO + MO for your $10,000?

ARPO: 50%MO: 50%
100% MO50/50100% ARPO
Portfolio after 10yr
$1.37M
Annual income
$436,579.10/yr
Blended yield
31.78%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

ARPO
Analyst Ratings
2
Buy
2
Hold
Consensus: Buy
Altman Z
-2.4
Piotroski
3/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-7.2% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ARPO buys
0
MO buys
0
No recent congressional trades found for ARPO or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricARPOMO
Forward yield90.91%6.36%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$2.67M$80.1K
Annual income after 10y$842,999.04$30,159.17
Total dividends collected$2.36M$74.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: ARPO vs MO ($10,000, DRIP)

YearARPO PortfolioARPO Income/yrMO PortfolioMO Income/yrGap
1← crossover$19,791$9,090.91$10,570$780.30+$9.2KARPO
2$37,991$16,814.71$11,381$1,032.90+$26.6KARPO
3$70,817$30,166.17$12,535$1,392.73+$58.3KARPO
4$128,326$52,552.16$14,193$1,920.91+$114.1KARPO
5$226,308$88,999.24$16,618$2,723.68+$209.7KARPO
6$388,835$146,685.82$20,263$3,993.80+$368.6KARPO
7$651,597$235,543.05$25,936$6,098.36+$625.7KARPO
8$1,066,101$368,892.48$35,166$9,775.01+$1.03MARPO
9$1,704,801$564,073.19$51,026$16,597.78+$1.65MARPO
10$2,667,136$842,999.04$80,113$30,159.17+$2.59MARPO

ARPO vs MO: Complete Analysis 2026

ARPOStock

Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Blue Ash, Ohio and currently employs 27 full-time employees. The firm is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway, which is being developed for the treatment of diabetic retinopathy (DR). AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha), which is being developed for the treatment of inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody directed at the same target as AKB-9778. ARP-1536 binds the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibiting its ability to interact with Tie-2. As of April 14, 2017, the Company had completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema. As of April 14, 2017, the Company had completed Phase Ia clinical trial in healthy volunteers for AKB-4924.

Full ARPO Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this ARPO vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ARPO vs SCHDARPO vs JEPIARPO vs OARPO vs KOARPO vs MAINARPO vs PMARPO vs BTIARPO vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.